Preparation of a 153Sm-5,10,15,20-tetrakis(4-methoxyphenyl) porphyrin complex as a possible therapeutic agent
Publish place: Iranian Journal of Nuclear Medicine، Vol: 23، Issue: 2
Publish Year: 1394
نوع سند: مقاله ژورنالی
زبان: English
View: 344
This Paper With 8 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_IRJNM-23-2_002
تاریخ نمایه سازی: 21 بهمن 1398
Abstract:
Introduction: Porphyrins are interesting derivatives with low toxicity, tumor avidity and rapid wash-out suggested as potential radiopharmaceuticals in radiolabeled form. In this work we report, synthesis, radiolabeling, quality control, stability, partition coefficient determination and biodistribution studies of 153Sm-5,10,15,20-tetrakis(4-methoxyphenyl) porphyrin (153Sm-4-MPP) in wild-type rats.
Methods: [153Sm]-4MPP was prepared using [153Sm]SmCl3 and 5,10,15,20-tetrakis(4-methoxyphenyl) porphyrin (H2-4MPP) for 18 h at 80-90°C. Stability of the complex was checked in final formulation and in presence of human serum for 24 h. The biodistribution of the labeled compound in vital organs of wild-type rats was studied. A detailed comparative pharmacokinetic study performed for 153Sm cation and [153Sm]-4-MPP up to 24h.
Results: The radiochemical purity of [153Sm]-4MPP was reported > 97±2% and > 99±0.5% by ITLC and HPLC, respectively. The specific activity was 220-230 MBq/mmol. The calculated partition coefficient for the compound was (log P=-1.09). The complex is mostly cleared from the circulation through kidneys and liver. The kidney:blood and kidney:muscle ratios 24 h post injection were 14.75 and 42.4, respectively. kidney/liver ratio was almost constant at all time intervals (0.6).
Conclusion: [153Sm]-4MPP was prepared at the optimized conditions and suitable characteristics. Further investigations such as biological studies of this agent on tumor-bearing models are needed.
Keywords:
Authors
Nasim Vahidfar
Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Amir Reza Jalilian
Radiopharmacy Research Group, Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran
Yousef Fazaeli
Radiopharmacy Research Group, Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran
Ali Bahrami-Samani
Radiopharmacy Research Group, Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran
مراجع و منابع این Paper:
لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :